03:24 PM EDT, 10/31/2024 (MT Newswires) -- Pulse Biosciences ( PLSE ) said Thursday that preliminary data from its first-in-human study of nanosecond pulsed field ablation technology showed reduction in benign thyroid nodule sizes by over 50% on average.

The pulses did not leave any residual fibrosis or scarring and symptoms improved within the first month, according to the company.

The company's shares fell 3% in recent trading.

Price: 17.18, Change: -0.54, Percent Change: -3.08